Aktis Oncology kicks 2026 IPO cycle off with $210m target
Radiopharma specialist Aktis will direct funds towards clinical trials of its most advanced candidates.
Therapy Area
Sanofi and Earendil Labs forge $2.56bn autoimmune deal
Biogen’s Tysabri to be used on England’s NHS for highly active MS
FDA approves Vanda Pharmaceuticals’ motion sickness drug Nereus
Genmab shelves Phase III lung cancer candidate
Sanofi buys hep B vaccine maker for $2.2bn
Novo beats Lilly to first FDA-approved GLP-1RA pill for obesity
UK approves Gilead’s twice-yearly HIV PrEP drug
